Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12880
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nayler, W G | en |
dc.contributor.author | Dillon, J S | en |
dc.contributor.author | Sturrock, W J | en |
dc.date.accessioned | 2015-05-16T02:37:49Z | |
dc.date.available | 2015-05-16T02:37:49Z | |
dc.date.issued | 1988-02-01 | en |
dc.identifier.citation | Clinical and Experimental Pharmacology & Physiology; 15(2): 93-103 | en |
dc.identifier.govdoc | 2856052 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/12880 | en |
dc.description.abstract | 1. Calcium antagonists, including verapamil, are now used widely in the management of patients with hypertension. 2. Six weeks of chronic therapy with verapamil (50 mg/kg per day, orally) to produce a plasma level of 80-100 ng/ml in Sprague-Dawley rats depletes cardiac noradrenaline (NA) without apparently causing beta 1 adrenoceptor 'up' regulation. 3. The effect of verapamil on cardiac NA is rapidly reversed upon verapamil withdrawal. 4. Chronic therapy with nisoldipine (100 mg/kg per day, orally) had no effect on cardiac NA. 5. Verapamil (50 mg/kg per day, orally) and nisoldipine (100 mg/kg per day, orally) therapy for 6 weeks prevented the time-dependent increase in systolic blood pressure in SHR rats. 6. Binding studies with (-)[3H]-D888 (desmethoxyverapamil) indicated that the affinity of the phenylalkylamine binding sites is higher in hearts of SHR relative to hearts from age-matched (25 weeks) WKY and SD, without any change in density. | en |
dc.language.iso | en | en |
dc.subject.other | Aging.metabolism | en |
dc.subject.other | Aniline Compounds.pharmacology | en |
dc.subject.other | Animals | en |
dc.subject.other | Blood Pressure.drug effects | en |
dc.subject.other | Calcium Channel Blockers.pharmacology | en |
dc.subject.other | Catecholamines.metabolism | en |
dc.subject.other | Dihydroalprenolol.diagnostic use | en |
dc.subject.other | Heart.drug effects | en |
dc.subject.other | Hypertension.physiopathology | en |
dc.subject.other | In Vitro Techniques | en |
dc.subject.other | Male | en |
dc.subject.other | Membranes.drug effects.metabolism | en |
dc.subject.other | Nisoldipine.blood.pharmacology | en |
dc.subject.other | Norepinephrine.metabolism | en |
dc.subject.other | Rats | en |
dc.subject.other | Rats, Inbred Strains | en |
dc.subject.other | Rats, Inbred WKY | en |
dc.subject.other | Receptors, Adrenergic, beta.drug effects.metabolism | en |
dc.subject.other | Verapamil.blood.pharmacology | en |
dc.title | Calcium antagonists and hypertension. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Clinical and Experimental Pharmacology & Physiology | en |
dc.identifier.affiliation | Department of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia | en |
dc.description.pages | 93-103 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/2856052 | en |
dc.type.austin | Journal Article | en |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.